Uwell Biopharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.04	0.45	-	-	-
Revenue Growth (YoY)	-92.22%	-	-	-	-
Cost of Revenue	0.01	0.15	-	-	-
Gross Profit	0.03	0.3	-	-	-
Selling, General & Admin	14.66	11.09	11.47	11.52	14.19
Research & Development	53.75	32.63	37.18	38.51	35.45
Operating Expenses	68.42	43.72	48.64	50.03	49.64
Operating Income	-68.39	-43.42	-48.64	-50.03	-49.64
Interest Expense	-0.15	-0.21	-0.22	-0.28	-0.42
Interest & Investment Income	2.32	0.83	0.62	0.26	0.05
Other Non Operating Income (Expenses)	0.02	1.92	3.08	8.58	0.01
EBT Excluding Unusual Items	-66.2	-40.87	-45.17	-41.47	-49.99
Pretax Income	-66.2	-40.87	-45.17	-41.47	-49.99
Net Income	-66.2	-40.87	-45.17	-41.47	-49.99
Net Income to Common	-66.2	-40.87	-45.17	-41.47	-49.99
Shares Outstanding (Basic)	154	117	89	57	24
Shares Outstanding (Diluted)	154	117	89	57	24
Shares Change (YoY)	31.58%	31.62%	55.95%	141.86%	11.16%
EPS (Basic)	-0.43	-0.35	-0.51	-0.73	-2.12
EPS (Diluted)	-0.43	-0.35	-0.51	-0.73	-2.12
Free Cash Flow	-54.36	-32.38	-42.64	-35.86	-43.65
Free Cash Flow Per Share	-0.35	-0.28	-0.48	-0.63	-1.85
Gross Margin	80.00%	66.89%	-	-	-
Operating Margin	-195391.43%	-9648.00%	-	-	-
Profit Margin	-189137.14%	-9082.67%	-	-	-
Free Cash Flow Margin	-155300.00%	-7196.22%	-	-	-
EBITDA	-60.33	-40.32	-45.53	-47.15	-47.57
D&A For EBITDA	8.06	3.1	3.12	2.88	2.07
EBIT	-68.39	-43.42	-48.64	-50.03	-49.64

Source: S&P Global Market Intelligence. Standard template. Financial Sources.